Centrus Energy (LEU) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Centrus Energy Q1 twenty twenty five Earnings Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Thursday, 05/08/2025. I would now like to turn the conference over to Neil Nagorajan, Head of Investor Relations. Please go ahead. Speaker1 Good morning. Thank yo ...

Financial Data and Key Metrics Changes - Novavax reported total revenue of $667 million for Q1 2025, a significant increase from $94 million in Q1 2024, driven by $622 million in product sales [28][29] - The company reduced current liabilities by over 60% compared to year-end 2024 and improved its cost structure by reducing combined R&D and SG&A costs by 24% year-over-year [29][36] - Net income for Q1 2025 was $519 million, or $2.93 per diluted share [35] Business Line Data and Key Metrics Changes - Product sales for Q1 2025 included $603 million from the closeout of the Canada and New Zealand APA agreements, allowing Novavax to retain cash previously received [29][33] - Supply sales of $14 million in Q1 2025 were primarily related to Matrix M adjuvant sales to licensed partners [34] Market Data and Key Metrics Changes - The partnership with Takeda has improved financial terms for Novavax in Japan, enhancing its position in the third-largest healthcare market globally [8][12] - Anticipated cash flows from licensed partners include $225 million in milestones from Sanofi and a $20 million upfront payment from Takeda [31][40] Company Strategy and Development Direction - The company is focusing on three strategic priorities: optimizing the partnership with Sanofi, leveraging its technology platform to forge additional partnerships, and advancing its tech platform and early-stage pipeline [9][43] - Novavax aims for non-GAAP profitability as early as 2027, with a disciplined investment strategy in high-potential value opportunities [7][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential approval of the BLA for the COVID vaccine and emphasized the importance of a non-mRNA protein-based vaccine option for U.S. consumers [10][11] - The company is actively seeking additional partnerships and collaborations to create multiple growth opportunities [12][13] Other Important Information - The company reiterated its full-year financial guidance for combined R&D and SG&A expenses of $475 million to $525 million, reflecting a 30% reduction compared to 2024 [30][38] - Novavax is working closely with the FDA on the parameters of the requested post-marketing commitment study related to its BLA [30][39] Q&A Session Summary Question: Nature of the post-marketing commitment FDA requested - Management has not publicly commented on the specifics of the study but is working diligently with the FDA to bring the process to a positive conclusion [46][47] Question: Target profile for KIC program and flu - The current study is designed to generate immunogenicity and safety data to inform the design of a phase three trial, not a pivotal trial [50][51] Question: Impact of the Utah Shield study on regulatory science - The Utah study is observational and not part of typical regulatory submissions; it informs consumer understanding rather than regulatory decisions [54][57] Question: Cash recognition from APA revenues - The $603 million recognized from Canada and New Zealand is non-cash, as the cash was received in prior years [71][72] Question: Safety profile of the combined vaccine - The study is designed to demonstrate immune response to both pathogens, with safety data to be supplemented from the immunogenicity data [79][80] Question: Confidence in receiving FDA approval of the BLA - Management sees a potential pathway forward for approval based on alignment on the post-marketing commitment [102][103]

Financial Data and Key Metrics Changes - Consolidated net sales revenue decreased by 10.4% compared to the prior year [13] - Underlying pretax income fell by 49.5% [13] - Underlying earnings per share declined by 47.4% [13] - The University of Michigan Consumer Sentiment Index dropped nearly 20 percentage points since the beginning of the year [12] - The company updated its full-year guidance to expect a low single-digit net sales revenue decline, a low single-digit underlying pretax income decline, and a low single-digit underlying earnings per share growth [13][50] Business Line Data and Key Metrics Changes - U.S. financial volume decreased by 15.7%, lagging behind U.S. brand volume, which was down 8.8% [14] - Net sales revenue per hectoliter in The Americas increased by 4.8% due to favorable net pricing growth and mix benefits [19] - EMEA and APAC financial volume decreased by 9.7% due to soft industry demand, but net sales revenue per hectoliter grew by 5.4% [19] Market Data and Key Metrics Changes - The beer industry faced significant macroeconomic pressures impacting consumer consumption behavior [7] - The competitive landscape in EMEA and APAC has intensified, with increased promotional intensity across channels [104] - The U.S. market is experiencing slower industry trends than expected, with a forecast of improvement in the latter half of the year [62][67] Company Strategy and Development Direction - The company is focusing on premiumizing its portfolio and strengthening core power brands [11][37] - Adjustments to capital expenditure plans are being made to prioritize high-growth initiatives while returning cash to shareholders [12][56] - The company aims to navigate short-term challenges while supporting long-term growth objectives [36][37] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the volatility in the global macroeconomic environment and its impact on consumer confidence and consumption trends [7][44] - The company remains committed to its long-term growth algorithm despite near-term challenges [11][37] - Management expressed confidence in the continued strengthening of core brands and the potential for future growth [10][21] Other Important Information - The company invested $88 million for an 8.5% equity stake in Fever Tree Drinks PLC and returned nearly $160 million to shareholders through dividends and share repurchases [20][43] - The company has executed over 40% of its share repurchase program within the first six quarters since its announcement [21][43] Q&A Session Summary Question: What has changed since the start of the year regarding the U.S. market? - Management indicated that the macroeconomic conditions were unexpected and have impacted consumer confidence and demand, leading to a slower industry performance than anticipated [62][64] Question: Are there concerns about losing market share? - Management confirmed that they have retained almost all of the share gained in 2023, with core brands showing strong performance and shelf space gains [72][73] Question: What are the expectations for the beer category growth? - Management noted that the softness in the industry is macro-driven and expects a return to more typical growth trends as the year progresses [100][101] Question: Can you elaborate on the competitive landscape in EMEA and APAC? - Management described the competitive pressures in the UK and Central and Eastern Europe, highlighting the need for a value-over-volume strategy and increased promotional activities [104][106]

SharkNinja (SN) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Thank you. I would now like to pass the conference over to your host, James Lamb, Senior Vice President of Investor Relations and Treasury. Thank you. You may proceed, James. Speaker1 Good morning, and welcome to SharkNinja's first quarter twenty twenty five earnings conference call. Earlier today, we issued our Q1 earnings release, which is available on the company's website at ir.sharkninja.com. A replay of today's webcast will also b ...

Crocs (CROX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 note this event is being recorded. I would now like to turn the conference over to Aaron Murphy, Senior Vice President, Investor Relations and Strategy for Crocs. Please go ahead. Speaker1 Good morning and thank you for joining us to discuss Crocs Inc. First quarter results. With me today are Andrew Rees, Chief Executive Officer and Susan Healy, Chief Financial Officer. Following their prepared remarks, we will open the call for your quest ...

Appian (APPN) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 note this event is being recorded. I would now like to turn the conference over to Jack Andrews, Vice President of Investor Relations. Please go ahead. Speaker1 Good morning, and thank you for joining us. Today, we'll review Appian's first quarter twenty twenty five financial results. With me are Matt Calkins, Chairman and Chief Executive Officer and Mark Lynch, Interim Chief Financial Officer. After prepared remarks, we'll open the call ...

Financial Data and Key Metrics Changes - Total net revenues increased by 43.6% year over year to $141,400,000, with significant contributions from all products [4][26] - Net income before income taxes for Q1 2025 was $71,300,000, a 145% increase year over year [28] - GAAP net income for Q1 2025 was $56,700,000, or $0.47 per basic share, reflecting a 144% increase year over year [28] - Non-GAAP net income for Q1 2025 was $86,600,000, or $0.71 per basic share, compared to $46,800,000 in Q1 2024 [28][29] Business Line Data and Key Metrics Changes - Firdapse generated revenue of $83,700,000, a 25.3% increase year over year [6][27] - Agamry's net product revenues totaled $22,000,000, compared to $1,200,000 in Q1 2024, marking its first full year of commercial availability [9][27] - Fycompa's net product revenue was $35,600,000, representing a year-over-year growth of 17.1% [11][28] Market Data and Key Metrics Changes - Approximately 20% to 25% of current Firdapse patients are cancer-associated LEMS patients, with expectations to increase this percentage through screening initiatives [49][90] - The market for LEMS is estimated at $1,200,000,000, with the company currently holding about 25% market penetration [94] Company Strategy and Development Direction - The company aims to expand its market leadership for Firdapse and Agamry while managing the transition of Fycompa post-patent expiry [12][15] - Strategic initiatives include enhancing patient access and focusing on business development opportunities that align with the company's goals [15][75] - The company is committed to advancing health equity by expanding access to therapies for underserved populations [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth momentum and achieving full-year revenue guidance of $545,000,000 to $565,000,000 [16][26] - The company is focused on executing strategic priorities and maintaining operational excellence [15][36] Other Important Information - The company ended Q1 2025 with cash and cash equivalents of $580,700,000, an increase from $517,600,000 at the end of 2024 [34] - Research and development expenses for Q1 2025 were $3,900,000, up from $2,600,000 in Q1 2024, reflecting ongoing investments in clinical studies [33] Q&A Session Summary Question: What contributed to Firdapse's growth this quarter? - Management indicated that approximately 15% to 20% growth is typical, and the strong performance in Q1 was partly due to recovery from the Change Healthcare incident [39][41] Question: What is the proportion of Fycompa patients on tablet versus oral suspension? - Approximately 85% of Fycompa patients are on the tablet formulation [44][62] Question: How is the uptake of Firdapse among small cell lung cancer patients? - Currently, 20% to 25% of LEMS patients on Firdapse are cancer-associated, with plans to increase this through screening efforts [49][90] Question: What are the company's current thoughts on business development? - The company remains focused on identifying immediately accretive opportunities and sees the current market dynamics as beneficial for its strategy [54][56] Question: How does the company plan to minimize brand erosion for Fycompa post-exclusivity? - Management noted that there is a tendency for anti-seizure medications to retain patients, which may help minimize brand erosion [70][72] Question: What is the company's market penetration for Firdapse? - The company estimates a market penetration of about 25% for Firdapse, with significant growth potential remaining [94][96]

Financial Data and Key Metrics Changes - The group-wide adjusted property EBITDA for Q1 2025 was approximately $341 million, while adjusted for VIP hold, it was approximately $313 million [9] - Operating expenses (OpEx) were reduced to $3.1 million per day in Q1 2025, down from $3.2 million in Q4 2024, with a target to exit Q2 2025 at $3 million per day [10][12] - Available liquidity stood at $3.3 billion, with consolidated cash on hand of approximately $1.2 billion as of the end of Q1 2025 [11] Business Line Data and Key Metrics Changes - Mass drop in Macau grew each month during the quarter, reaching record highs at both City of Dreams and Studio City, with market share increasing from 14.7% in Q4 2024 to 15.7% in Q1 2025 [4][5] - Studio City property EBITDA increased by 20% quarter-over-quarter, demonstrating the positive impact of recent renovations [6] - City of Dreams Mediterranean and Cypress achieved a 10% year-over-year growth in property EBITDA for Q1 2025 [7] Market Data and Key Metrics Changes - Property visitation in Macau grew by 30% year-over-year during the May Golden Week [4] - Golden Week visitation was up 40% year-over-year, indicating strong demand and market recovery [55] Company Strategy and Development Direction - The company is focused on maintaining high-quality product offerings and strategic marketing to drive business momentum [6] - There is an ongoing strategic review of City of Dreams Manila, with potential buyers currently engaged in the process [22] - The company aims to balance capital allocation between share buybacks and debt reduction, with a focus on maximizing shareholder value [12][48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the business momentum, citing strong performance in Macau and a stable market share despite new competition [4][18] - The company noted that the competitive environment in the Philippines has impacted performance, prompting adjustments in cost structure and marketing programs [7] - Management highlighted the importance of Chinese policy in supporting domestic consumption and travel, which is crucial for future growth [29] Other Important Information - The House of Dancing Water show was relaunched successfully, expected to drive additional visitation to City of Dreams [5] - The company has repurchased approximately $165 million in MLCO ADSs in 2025, taking advantage of low valuations in the equity markets [12] Q&A Session Summary Question: Impact of London Legrand opening on competition - Management reported no significant impact on market share or business from the opening of London Legrand, maintaining strong performance in Q1 [15][19] Question: Update on City of Dreams Manila strategic review - The strategic review is ongoing, with potential buyers signing NDAs and working through questions [22] Question: Signs of weakness on the gaming floor - Management indicated no signs of weakness post-Golden Week, with continued strong performance observed [27][32] Question: CapEx guidance for the year - Full year CapEx guidance remains unchanged at $415 million, with the completion of Sri Lanka highlighted as a major project [33] Question: OpEx expectations for Q2 - OpEx guidance for Q2 is expected to be around $3 million per day, excluding costs related to House of Dancing Water and residency concerts [36][37] Question: Non-gaming spend insights during Golden Week - Retail and F&B activity was strong during Golden Week, although high-end luxury retail continues to face challenges [57][58]

Financial Data and Key Metrics Changes - The company reported a 12% growth in royalty receipts, reflecting strong performance in a diversified portfolio [5][19] - Portfolio receipts grew by 17% to $839 million, driven by milestone payments and strong underlying performance [20][22] - The company repurchased $723 million of its shares in the first quarter, part of a $2 billion share repurchase plan for 2025 [6][24] Business Line Data and Key Metrics Changes - The cystic fibrosis franchise, including Trelegy and Xtandi, was a key driver of growth in royalty receipts [19] - Milestone and other contractual receipts amounted to $51 million, including a significant milestone payment of $27 million [20] Market Data and Key Metrics Changes - The company expects portfolio receipts for 2025 to be between $2.975 billion and $3.125 billion, reflecting growth of 6% to 12% [8][27] - The weakening of the U.S. Dollar is expected to provide a tailwind to revenue growth [8] Company Strategy and Development Direction - The company is focused on a dynamic capital allocation framework, balancing share repurchases with attractive royalty acquisitions [6][24] - A new Phase III R&D funding collaboration with Biogen for latifilumab in lupus was announced, indicating a focus on high-potential therapies [7][10] - The company aims to leverage its unique business model to drive shareholder value in the growing biopharma market [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong financial performance in 2025, citing a robust pipeline and effective capital allocation [32][34] - The company does not expect significant impacts from tariffs on its royalties, as tariffs are typically incurred upstream of royalty-bearing sales [31][50] Other Important Information - The company raised its full-year 2025 guidance, reflecting strong portfolio performance and favorable currency effects [8][27] - The company maintains significant financial capacity with cash and equivalents close to $1.1 billion and investment-grade debt [22][23] Q&A Session Questions and Answers Question: Impact of regulatory and policy uncertainties on deal-making - Management noted that while there is policy uncertainty, it has not significantly impacted their opportunity set, and the investment environment remains strong [39][40] Question: Updates on Vertex cystic fibrosis portfolio negotiations - No updates were provided on the Vertex situation, but management remains confident in their position regarding KALYDECO [41] Question: Potential for Royalty Pharma to step in as a funding source - Management highlighted the significant capital needs of the biotech sector, presenting an opportunity for Royalty Pharma to provide necessary funding [48][49] Question: Clinical benefit of echopipam and market parallels - Management emphasized the unmet need in the Tourette syndrome market and the potential for echopipam to fill this gap, while also acknowledging the TD market as an interesting comparison [77] Question: Timing for potential dispute with Vertex - Management could not comment on the timing of any potential dispute with Vertex [79]

Vital Farms (VITL) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Vital Farms First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand it over to your host, John Mills with ICR. Speaker1 Good morning and welcome to Vital F ...